Dr. Douglas Mark Rouff

D.D.S. | Dentist



  
  388 Linden Ave, Doylestown
  Pennsylvania, 18901-4408

  248-496-7522    Maps & Directions
Dr. Douglas Mark Rouff is a Doylestown, Pennsylvania based Dentist who is specialized in General Practice Dentistry. He may accept the Medicare-approved amount. Patients may be billed for more than the Medicare deductible and coinsurance. His current practice location is 388 Linden Ave, Doylestown. Patients can reach him at 248-496-7522.
Dr. Douglas Mark Rouff is the primary dental care provider for patients of all ages. He is responsible for the diagnosis, treatment, management and overall coordination of services related to patients' oral health needs.
Complete Profile:
Dr. Douglas Mark Rouff speciality, credentials, practice address, contact phone number and fax are as below. Patients can directly walk in or can call on the below given phone number for appointment.
Name: Dr. Douglas Mark Rouff
Specialization: Dentist
Gender:Male
Credentials: D.D.S.
Accepts Medicare Assignment:May Accept
Practice Address:388 Linden Ave, Doylestown,
Pennsylvania, 18901-4408
Phone:248-496-7522
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS). NPI details are as mentioned below.
PAC ID: 7315245123
Enrollment ID: I20160412001140
NPI Number: 1740318187
NPI Enumeration Date: 28 Feb, 2007
NPI Last Update On: 22 May, 2020

Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address: 388 Linden Ave,
Doylestown, Pennsylvania
Zip: 18901-4408
Phone Number: 248-496-7522
Patients can reach Dr. Douglas Mark Rouff at 388 Linden Ave, Doylestown, Pennsylvania or can call to book an appointment on 248-496-7522. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 May, 2024.

Comments/ Reviews: